ABSTRACT
BACKGROUND: Bronchial fibroblasts play a key role in airway remodelling in asthma. They regulate epithelial cell functions such as proliferation through growth factors, cytokines, chemokines and exosomes. The role of exosomes in the communication between epithelial cells and fibroblasts by vehiculing these mediators in asthma remains to be determined. OBJECTIVE: To evaluate the role of exosomes released by bronchial fibroblasts on epithelial cell proliferation in severe asthma. METHODS: Exosomes were obtained from culture media of primary bronchial fibroblasts and characterized using Western blot, electron microscopy and flow cytometry. Uptake profile of fluorescent-labelled exosomes in epithelial cells was assessed by flow cytometry. Exosome cytokine content was analysed by Cytokine Arrays. Bronchial epithelial cell proliferation was evaluated by BrdU incorporation test. Exosome biogenesis/release was blocked using sphingomyelinase inhibitor. Plasmid transfection was used to modulate transforming growth factor beta 2 (TGF-ß2) gene expression. RESULTS: We showed that bronchial fibroblasts secreted exosomes, which were internalized by bronchial epithelial cells. Exosomes of severe asthmatic subjects' fibroblasts showed a lower level of TGF-ß2 and significantly increased the epithelial cell proliferation of both healthy and severe asthmatic subjects compared to healthy controls' exosomes. Overexpression of TGF-ß2 in severe asthmatics' fibroblasts induced enhanced TGF-ß2 in exosomes leading to a reduced proliferation of epithelial cells, whereas knockdown of TGF-ß2 enhanced epithelial cell proliferation. CONCLUSION: Our study shows that exosomes are involved in fine-tuning intercellular communication in asthma. Exosomes of severe eosinophilic asthmatics' fibroblasts can contribute to airway remodelling, at least in part, by modulating epithelial cell proliferation observed in severe asthma.
Subject(s)
Asthma/diagnosis , Asthma/metabolism , Exosomes/metabolism , Fibroblasts/metabolism , Transforming Growth Factor beta2/metabolism , Adult , Aged , Asthma/immunology , Biomarkers , Case-Control Studies , Cell Proliferation , Cytokines/metabolism , Eosinophils/metabolism , Epithelial Cells/metabolism , Female , Humans , Male , Middle Aged , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology , Severity of Illness Index , Young AdultSubject(s)
Asthma/genetics , Cellular Senescence/genetics , Fibroblasts/metabolism , Telomere Shortening , HumansABSTRACT
BACKGROUND: Allergic asthma is characterized by inflammation and airway remodeling. Bronchial epithelium is considered a key player in coordinating airway wall remodeling. In mild asthma, the epithelium is damaged and fails to proliferate and to repair, whereas in severe asthma, the epithelium is highly proliferative and thicker. This may be due to different regulatory mechanisms. The purpose of our study was to determine the role of miRNAs in regulating proliferation of bronchial epithelial cells obtained from severe asthmatic subjects in comparison with cells obtained from mild asthmatics and healthy controls. METHODS: Human bronchial epithelial cells (BEC) were isolated by bronchoscopy from bronchial biopsies of healthy donors and patients with mild and severe asthma. MiRNA expression was evaluated using the TaqMan low-density arrays and qRT-PCR. Transfection studies of bronchial epithelial cells were performed to determine the target genes. Cell proliferation was evaluated by BrdU incorporation test. RESULTS: MiR-19a was upregulated in epithelia of severe asthmatic subjects compared with cells from mild asthmatics and healthy controls. Functional studies based on luciferase reporter and Western blot assays suggest that miR-19a enhances cell proliferation of BEC in severe asthma through targeting TGF-ß receptor 2 mRNA. Moreover, repressed expression of miR-19a increased SMAD3 phosphorylation through TGF-ß receptor 2 signaling and abrogated BEC proliferation. CONCLUSION: Our study uncovers a new regulatory pathway involving miR-19a that is critical to the severe phenotype of asthma and indicates that downregulating miR-19a expression could be explored as a potential new therapy to modulate epithelium repair in asthma.
Subject(s)
Asthma/genetics , MicroRNAs/genetics , Protein Serine-Threonine Kinases/genetics , RNA Interference , Receptors, Transforming Growth Factor beta/genetics , Respiratory Mucosa/metabolism , 3' Untranslated Regions , Adult , Aged , Asthma/diagnosis , Biopsy , Case-Control Studies , Cell Proliferation , Female , Forced Expiratory Volume , Gene Expression Regulation , Humans , Male , Middle Aged , Phosphorylation , RNA, Messenger/genetics , Receptor, Transforming Growth Factor-beta Type II , Respiratory Mucosa/pathology , Severity of Illness Index , Smad3 Protein/metabolism , Sputum/cytology , Young AdultABSTRACT
BACKGROUND: Cysteinyl leukotrienes (CysLTs) play an important role in airway inflammation in asthma but their role in airway remodeling is not completely known. METHODS: CysLTs receptors and procollagen I(α(1)) mRNA were determined by qPCR. Procollagen protein production was measured by RIA and TGF-ß(1) expression was determined by ELISA. TGF-ß receptor expression was assessed by western blots. RESULTS: CysLT1R, TGF-ß-R1 and active TGF-ß(1) are highly expressed in cells from asthmatics compared to normal controls. LTD(4) increased significantly procollagen I(α(1)) mRNA and protein expression in fibroblasts from asthmatics. This increase was blocked by CysLTs receptor antagonist. LTD(4) increased significantly mRNA expression of TGF-ß(1) and active form production in fibroblasts from asthmatics. Inhibition of TGF-ß(1) signaling blocked LTD(4)-induced procollagen I(α(1)) expression. CONCLUSIONS: Fibroblasts from asthmatic subjects express high level of CysLT1R. LTD(4) regulates procollagen I(α(1)) transcription in fibroblasts derived from asthmatic patients by modulating TGF-ß(1) expression. This suggests that CysLTs may play a role in regulating collagen deposition in asthma.
Subject(s)
Asthma/metabolism , Bronchi/metabolism , Collagen/biosynthesis , Cysteine/pharmacology , Fibroblasts/metabolism , Immunologic Factors/pharmacology , Leukotrienes/pharmacology , Transforming Growth Factor beta1/metabolism , Adult , Asthma/pathology , Bronchi/chemistry , Bronchi/pathology , Cells, Cultured , Female , Fibroblasts/chemistry , Humans , MaleABSTRACT
BACKGROUND AND OBJECTIVE: Smoking cigarettes increases the risk of developing various types of human diseases, including cancers and periodontitis. As gingival epithelial cells are known to play an active role in innate immunity via the secretion of a wide variety of mediators, and as these cells are the first ones exposed to environmental stimuli such as cigarette smoke, we sought to investigate the effects of whole cigarette smoke on normal human gingival epithelial cells and tissue. MATERIAL AND METHODS: Human gingival epithelial cells were extracted from healthy nonsmokers and used either as a monolayer or as an engineered human oral mucosa to investigate the effect of whole cigarette smoke on cell growth, apoptosis and wound repair/migration. RESULTS: Our findings show that when gingival epithelial cells were exposed once to whole cigarette smoke, this resulted in a significant inhibition of cell growth through an apoptotic pathway, as confirmed by an increase of Bax and a decrease of Bcl-xL and caspase-3 activity. Cigarette smoke also inhibited epithelial cell migration. These effects may explain the disorganization of the engineered human oral mucosa tissue when exposed to whole cigarette smoke. CONCLUSION: Exposure to whole cigarette smoke markedly inhibits epithelial cell growth through an apoptosis/necrosis pathway that involves Bax and Bcl-xL proteins and caspase-3 activity. Cigarette smoke also disrupts epithelial cell migration, which may negatively affect periodontal wound healing.
Subject(s)
Apoptosis , Gingiva/drug effects , Mouth Mucosa/drug effects , Tobacco Smoke Pollution/adverse effects , Wound Healing/drug effects , Annexins/biosynthesis , Cell Movement/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Fibroblasts/drug effects , Gingiva/cytology , Humans , Necrosis , Propidium/metabolism , Statistics, Nonparametric , bcl-2-Associated X Protein/biosynthesis , bcl-X Protein/biosynthesisABSTRACT
BACKGROUND: Corticosteroid insensitivity in asthmatics is associated with an increased expression of glucocorticoid receptor-beta (GR-beta) in many cell types. T-helper type 17 (Th17) cytokine (IL-17A and F) expressions increase in mild and in difficult-to-treat asthma. We hypothesize that IL-17A and F cytokines alone or in combination, induce the expression of GR-beta in bronchial epithelial cells. OBJECTIVES: To confirm the expression of the GR-beta and IL-17 cytokines in the airways of normal subjects and mild asthmatics and to examine the effect of cytokines IL-17A and F on the expression of GR-beta in bronchial epithelial cells obtained from normal subjects and asthmatic patients. METHODS: The expression of IL-17A and F, GR-alpha and GR-beta was analysed in bronchial biopsies from mild asthmatics and normal subjects by Q-RT-PCR. Immunohistochemistry for IL-17 and GR-beta was performed in bronchial biopsies from normal and asthmatic subjects. The expression of IL-6 in response to IL-17A and F and dexamethasone was determined by Q-RT-PCR using primary airway epithelial cells from normal and asthmatic subjects. RESULTS: We detected significantly higher levels of IL-17A mRNA expression in the bronchial biopsies from mild asthmatics, compared with normal. GR-alpha expression was significantly lower in the biopsies from asthmatics compared with controls. The expression of IL-17F and GR-beta in biopsies from asthmatics was not significantly different from that of controls. Using primary epithelial cells isolated from normal subjects and asthmatics, we found an increased expression of GR-beta in response to IL-17A and F in the cells from asthmatics (P< or =0.05). This effect was only partially significant in the normal cells. Dexamethasone significantly decreased the IL-17-induced IL-6 expression in cells from normal individuals but not in those from asthmatics (P< or =0.05). CONCLUSION: Evidence of an increased GR-beta expression in epithelial cells following IL-17 stimulation suggests a possible role for Th17-associated cytokines in the mechanism of steroid hypo-responsiveness in asthmatic subjects.
Subject(s)
Asthma/immunology , Bronchi/immunology , Epithelial Cells/immunology , Interleukin-17/metabolism , Receptors, Glucocorticoid/metabolism , Adult , Cells, Cultured , Dexamethasone/pharmacology , Female , Humans , Interleukin-17/immunology , Male , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Helper-Inducer/immunology , Up-Regulation/drug effectsABSTRACT
BACKGROUND: Bronchial epithelium is considered a key player in coordinating airway wall remodelling. The function of epithelial cells can be modulated by the underlying fibroblasts through autocrine and paracrine mechanisms. OBJECTIVE: To investigate the effect of phenotypic changes in bronchial fibroblasts from asthmatic subjects on epithelial cell proliferation. METHODS: Epithelial cells and fibroblasts derived from bronchial biopsies of asthmatic and healthy controls were cultured in an engineered model. Proliferation was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromid (MTT). Epidermal growth factor receptor (EGFR), cyclin-dependent kinase inhibitors p21 and p27 were measured by western blots. Total and active forms of transforming growth factor (TGF)-ß1 were measured using ELISA and bioassay. TGF-ß was inhibited using a recombinant TGF-ß soluble receptor II protein. RESULTS: Proliferation of epithelial cells from asthmatics (AE) is increased when cells were cultured with fibroblasts from normal controls (NF). Fibroblasts from asthmatics (AF) significantly decreased the proliferation of epithelial cells from healthy subjects (NE). Activation of p21, p27, EGFR and TGF-ß1 reflects the proliferation data by decreasing in AE cultured with NF and increasing in NE cultured with AF. Neutralization of TGF-ß increased proliferation of epithelial cells cultured in the asthmatic model. CONCLUSION: Fibroblasts from asthmatic subjects regulate epithelial cell prolifearation, and TGF-ß signalling may represent one of the pathway involved in these interactions.
Subject(s)
Asthma/metabolism , Epithelial Cells/metabolism , Fibroblasts/metabolism , Respiratory Mucosa/metabolism , Signal Transduction/physiology , Asthma/immunology , Asthma/pathology , Blotting, Western , Bronchi/immunology , Bronchi/metabolism , Bronchi/pathology , Cell Communication/physiology , Cell Proliferation , Cells, Cultured , Coculture Techniques , Cyclin-Dependent Kinase Inhibitor Proteins/biosynthesis , Cyclin-Dependent Kinase Inhibitor Proteins/immunology , Enzyme-Linked Immunosorbent Assay , Epithelial Cells/immunology , Epithelial Cells/ultrastructure , ErbB Receptors/metabolism , Fibroblasts/immunology , Fibroblasts/ultrastructure , Humans , Microscopy, Electron, Scanning , Respiratory Mucosa/immunology , Respiratory Mucosa/pathology , Reverse Transcriptase Polymerase Chain Reaction , Tissue Engineering , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/immunologyABSTRACT
Normalisation of eosinophil counts in sputum of asthmatic patients reduces eosinophilic exacerbations. However, the effect of this strategy on airway remodelling remains to be determined. We compared bronchial inflammation and collagen deposition after 2 yrs of treatment guided by either sputum eosinophils (sputum strategy, SS) or by clinical criteria (clinical strategy, CS). As a pilot study, 20 mild asthmatic patients were randomly assigned to CS or SS strategies. Bronchial biopsies were obtained when minimum treatment needed to maintain control was identified and this was continued for 2 yrs. Biopsies were immunostained for inflammatory cells, mucin 5A (MUC5A) and collagen. The mean dose of inhaled corticosteroids at the start and end of the study was similar in both SS and CS groups. Forced expiratory volume in 1 s increased in both groups at the study end. In SS, mucosal lymphocyte and eosinophil counts, but not neutrophils, were reduced at the end of the study. In CS, only activated eosinophil and neutrophil counts decreased. MUC5A staining decreased in SS but not CS. No change in collagen deposition underneath the basement membrane was observed in either strategy. Treatment strategies that normalise sputum eosinophils also reduce mucosal inflammatory cells and MUC5A expression, but do not change subepithelial collagen deposition in mild to moderate asthma.
Subject(s)
Airway Remodeling , Asthma/immunology , Bronchitis/immunology , Eosinophils , Sputum/cytology , Adult , Asthma/pathology , Biopsy , Bronchitis/pathology , Cell Count , Female , Humans , Male , Pilot ProjectsABSTRACT
In 2008, many thousands of articles were published on the subject of allergic disease with over 200 reviews, editorials and original papers in Clinical & Experimental Allergy alone. These represent a considerable amount of data and even the most avid reader could only hope to assimilate a small fraction of this knowledge. There is therefore a pressing need for the key messages that emerge from a journal such as Clinical & Experimental Allergy to be summarized by experts in the field in a form that highlights the significance of the developments and sets them in the context of important findings in the field published in other journals. This also has the advantage of making connections between new data in conditions such as asthma, where articles often appear in different sections of the journal. As can be seen from this review, the body of work is diverse both in terms of the disease of interest and the discipline that has been used to investigate it. However, taken as a whole, we hope that the reader will gain a flavour of where the field is mature, where there remain controversies and where the cutting edge is leading.
Subject(s)
Biomedical Research/history , Hypersensitivity/history , Periodicals as Topic/history , Animals , Biomedical Research/methods , Biomedical Research/trends , History, 21st Century , Humans , Hypersensitivity/etiology , Hypersensitivity/metabolism , Hypersensitivity/therapyABSTRACT
BACKGROUND: Mechanical strain and cytokine stimulation are two important mechanisms leading to airway remodeling in asthma. The effect of mechanical strain on cytokine secretion in airway fibroblasts is not known. The aim of this study was to determine whether bronchial and nasal fibroblasts differentially alter cytokine secretion in response to mechanical strain. METHODS: We measured secretion of the pro-fibrotic cytokine, interleukin-6 (IL-6), and the pro-inflammatory cytokines, IL-8 and monocyte chemotactic protein 1, before and after mechanical strain in bronchial fibroblasts obtained from asthmatic patients [asthmatic bronchial fibroblasts (BAF)] and normal volunteers [normal bronchial fibroblasts (BNF)], and in nasal fibroblasts (NF) obtained from nasal polyps. Cells were grown on flexible membranes and a mechanical strain of 30% amplitude, 1 Hz frequency was applied for 3, 6 and 24 h. Control cells were unstrained. IL-6, IL-8 and monocyte chemotactic protein 1 was measured after 24 h strain using enzyme-linked immunoassay; mRNA was measured by real time polymerase chain reaction. We also measured mRNA for versican, a matrix proteoglycan, known to be upregulated in the asthmatic airway wall. RESULTS: In unstrained conditions, no differences in cytokine secretion were observed. After 24 h strain, BAF secreted more IL-6 than BNF. Mechanical strain increased IL-8 mRNA in BAF, BNF and NF; and IL-6 and versican mRNA, in BAF, only. CONCLUSIONS: Cytokine responses to mechanical strain varied in different airway fibroblast populations, and depended on the site of origin, and the underlying inflammatory state. Strain resulted in IL-6 upregulation and increased message for extracellular matrix protein in bronchial fibroblasts from asthmatic patients only, and may reflect these patients' propensity for airway remodeling.
Subject(s)
Asthma/pathology , Biomechanical Phenomena/genetics , Bronchi/pathology , Chemokines/genetics , Cytokines/genetics , Fibroblasts/pathology , Adolescent , Adult , Asthma/immunology , Bronchi/immunology , Case-Control Studies , Extracellular Matrix Proteins/genetics , Female , Fibroblasts/immunology , Humans , Interleukin-6/genetics , Male , Up-Regulation , Young AdultABSTRACT
The neuroendocrine mechanism underlying seasonal changes in gonadal activity of the jerboa, a desert hibernating rodent adapted to harsh climatic conditions, are poorly understood. We investigated the role of the pineal gland and melatonin in the photoperiodic control of hypothalamic gonadotropin-releasing hormone (GnRH). Intact and pinealectomized male jerboas were subjected to short photoperiod, while others were kept under long photoperiod and injected daily with melatonin or vehicle. Testes activity was monitored by evaluating the testes volume during 10 weeks. GnRH immunoreactivity was investigated quantitatively with image analysis. Following melatonin administration, the hormone peaked in plasma after 30 min, with return to control levels 2.5 h later. Exposure to short photoperiod and melatonin resulted in marked increase in the number of GnRH-containing cells in the preoptic area and mediobasal hypothalamus, whereas GnRH immunoreactivity of fibers and terminals in the median eminence decreased under these conditions. The findings indicate that in the jerboa short photoperiod induces testicular regression by prolonging the duration of melatonin as an endocrine signal. This mechanism probably involves inhibition of GnRH release in the median eminence, with consequent accumulation of GnRH in perikarya of the preoptic area and mediobasal hypothalamus. Interestingly, GnRH cells of the median eminence did not appear to be influenced by the photoperiod and pineal melatonin, whereas their number was increased by exogenous melatonin. The latter data suggest for the first time the involvement of an extrapineal melatonin, whose origin remains to be identified, in the modulation of the GnRH regulatory system in rodents.
Subject(s)
Gonadotropin-Releasing Hormone/metabolism , Hypothalamus/metabolism , Melatonin/physiology , Photoperiod , Pineal Gland/physiology , Analysis of Variance , Animals , Cell Count/methods , Hypothalamus/cytology , Hypothalamus/drug effects , Immunohistochemistry/methods , Male , Melatonin/administration & dosage , Neurons/metabolism , Pineal Gland/surgery , Radioimmunoassay/methods , Rodentia , Testis/metabolismABSTRACT
BACKGROUND: Remodelling of the asthmatic airway includes increased deposition of proteoglycan (PG) molecules. One of the stimuli driving airway remodelling may be excessive mechanical stimulation. OBJECTIVE: We hypothesized that fibroblasts from asthmatic patients would respond to excessive mechanical strain with up-regulation of message for PGs. METHODS: We obtained fibroblasts from asthmatic patients (AF) and normal volunteers (NF) using endobronchial biopsy. Cells were maintained in culture until the fifth passage and then grown on a flexible collagen-coated membrane. Using the Flexercell device, cells were then subjected to cyclic stretch at 30% amplitude at 1 Hz for 24 h. Control cells were unstrained. Total RNA was extracted from the cell layer and quantitative RT-PCR performed for decorin, lumican and versican mRNA. RESULTS: In unstrained cells, the expression of decorin mRNA was greater in AF than NF. With strain, NF showed increased expression of versican mRNA and AF showed increased expression of versican and decorin mRNA. The relative increase in versican mRNA expression with strain was greater in AF than NF. CONCLUSIONS: These data support the hypothesis that proteoglycan message is increased in asthmatic fibroblasts subject to mechanical strain. This finding has implications for the mechanisms governing airway wall remodelling in asthma.
Subject(s)
Asthma/metabolism , Fibroblasts/metabolism , Proteoglycans/metabolism , Adult , Analysis of Variance , Asthma/pathology , Bronchi/pathology , Case-Control Studies , Female , Humans , Male , Reverse Transcriptase Polymerase Chain Reaction , Stress, MechanicalABSTRACT
BACKGROUND: In bronchial mucosa, T cells are in close association with fibroblasts. This cell contact raises the possibility of cross-talk between the two cell types through cytokines, such as interleukin-4 (IL-4). OBJECTIVE: We postulated that IL-4 may modulate collagen synthesis and degradation in the fibroblasts of asthmatics. METHODS: Bronchial fibroblasts from asthmatics (BAF) and normal controls (BNF) were stimulated with IL-4. Procollagen I gene expression and protein production were measured by real-time PCR, RT-PCR, and radioimmunoassay. The effect of IL-4 on the regulation of procollagen I (alpha1) promoter was studied through transient cell transfections. The implication of Sp1 and AP-1 in regulating IL-4-induced procollagen I (alpha1) production was determined. The effect of IL-4 on metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) production and gene expression was evaluated. RESULTS: Following IL-4 stimulation, there was a significant increase in the expression of mRNA of procollagen I (alpha1) by human bronchial fibroblasts of asthmatics and controls. IL-4 has a dose-response effect on mRNA, with a maximal effect at 5 ng/mL, as determined by real-time PCR. The maximal increase in procollagen I (alpha1) was observed at 6 h after IL-4 stimulation in both BNF and BAF. BAFs have a greater increase in the procollagen I (alpha1)/beta2 microglobulin ratio after 6 h of IL-4 stimulation (4.1 x 10-2+/-0.03 to 20.8 x 10-2+/-0.1) compared with BNF (2.9 x 10-2+/-0.006 to 9.2 x 10-2+/-0.08) (P=0.001). In transient transfection experiments, IL-4 increased promoter activity by threefold in BAF and BNF. Sp1 was up-regulated after IL-4 stimulation and AP-1 was down-regulated as shown by electrophoretic mobility shift assay. IL-4 decreased MMP-2 protein and mRNA levels, and did not alter TIMP-2 production. CONCLUSIONS: IL-4 positively regulates procollagen I (alpha1) transcription by direct promoter activation and increases the TIMP-2/MMP-2 ratio, thereby supporting the profibrotic effect of this cytokine. Thus, this study emphasizes that IL-4 may be considered as a link between inflammation and collagen deposition observed in asthmatic airways.
Subject(s)
Asthma/metabolism , Bronchi/metabolism , Interleukin-4/pharmacology , Procollagen/biosynthesis , Respiratory Mucosa/metabolism , Cells, Cultured , Fibroblasts/metabolism , Gene Expression Regulation/drug effects , Humans , Interleukin-4/physiology , Matrix Metalloproteinase 2/biosynthesis , Polymerase Chain Reaction/methods , Procollagen/genetics , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-2/biosynthesis , TransfectionABSTRACT
This study aimed to determine whether there is a persistent or different type of airway inflammation in patients with an incomplete reversibility of airflow obstruction (IRAO) despite optimal treatment and if so, whether it is associated with an accelerated decline of pulmonary function. Fifteen asthmatic patients with IRAO, and 23 with complete reversibility of airflow obstruction (CRAO) had a spirometry and an induced-sputum (IS) analysis. Past FEV1 values were recorded over 2-12 years during periods of stable asthma. Medians (range) for IS cell differentials were: lymphocytes, 0(0-3)/1(0-2)%; neutrophils, 56(13-88)/38(3-84)% and eosinophils, 2.0(0-82)/4.0(0-68)%, (all P>0.05). Among non-smoking patients, those with IRAO had more neutrophils in IS than those with CRAO (P=0.019). Mean (+/-SEM) yearly fall in FEV1 in IRAO or CRAO patients was 54+/-21/84+/-16 ml/year (P>0.05, predicted age-related decline < or = 26 ml/year, P=0.0008). In the whole group of asthmatic patients, decline of FEV1/year was inversely correlated with the % neutrophils in sputum (r(s)=-0.436, P=0.008) and, in IRAO patients, with the duration of asthma (r(s)=-0.559, P=0.037). In conclusion, persistent airway inflammation and increased decline in pulmonary function can be observed in both asthmatic patients with IRAO/CRAO and are of similar magnitude. Non-smoking patients with IRAO had more neutrophils in IS than CRAO.
Subject(s)
Airway Obstruction/physiopathology , Asthma/physiopathology , Adrenal Cortex Hormones/therapeutic use , Aged , Asthma/drug therapy , Female , Forced Expiratory Volume/physiology , Humans , Male , Middle Aged , Retrospective Studies , Smoking/physiopathology , Sputum/cytology , Vital Capacity/physiologyABSTRACT
BACKGROUND: Tissue eosinophils express more membrane receptors and release more mediators than blood eosinophils, suggesting that migration from blood to tissue modulates eosinophil phenotype and functions. OBJECTIVE: We postulated that eosinophil passage through endothelial basement membrane, an important step of eosinophil migration into tissue, may be responsible for some of these changes. METHOD: We previously showed that 5-oxo-6, 8, 11, 14-eicosatetraenoic acid (5-oxo-ETE) in combination with IL-5 promotes eosinophil migration through Matrigel, a mouse tumour cell-derived basement membrane. Using this model, we evaluated the effect of trans-Matrigel migration on purified human blood eosinophil expressions of CD44, CD69 and HLA-DR that either increase or appear on activated eosinophils, and releases of peroxidase (EPO), leukotriene (LT) C(4) and granulocyte-monocyte colony stimulating factor (GM-CSF). RESULTS: IL-5, but not 5-oxo-ETE, increased eosinophil expression of CD44 and CD69. Migration of eosinophils through Matrigel significantly increased CD44 expression level over the one induced by IL-5 (P = 0.0001). Migration through Matrigel did not modify CD69 expression compared with the one obtained in the presence of IL-5 alone; however, incubation of eosinophils on Matrigel decreased IL-5-induced CD69 (P = 0.0001). Trans-Matrigel migration did not modify HLA-DR expression, nor EPO, LTC(4) and GM-CSF releases. CONCLUSION: These data show that in vitro trans-Matrigel migration and Matrigel contact modulate eosinophil membrane receptor expression. Consequently, they suggest that migration through basement membrane mediates changes in cell-surface phenotype observed on activated eosinophils and probably prepares them for interactions with tissue components and cells.
Subject(s)
Basement Membrane/metabolism , Cell Movement/physiology , Eosinophils/metabolism , Hyaluronan Receptors/biosynthesis , Adolescent , Adult , Arachidonic Acids/pharmacology , Asthma/metabolism , Asthma/physiopathology , Basement Membrane/cytology , Basement Membrane/drug effects , Biocompatible Materials/pharmacology , Cell Movement/drug effects , Collagen/pharmacology , Cytokines/drug effects , Cytokines/metabolism , Drug Combinations , Eosinophils/drug effects , Female , Forced Expiratory Volume/physiology , Granulocyte-Macrophage Colony-Stimulating Factor/drug effects , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Hyaluronan Receptors/drug effects , Inflammation Mediators/metabolism , Interleukin-5/pharmacology , Laminin/pharmacology , Male , Middle Aged , Predictive Value of Tests , Proteoglycans/pharmacology , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/drug effectsABSTRACT
BACKGROUND: Pathophysiology of corticosteroid (CS)-resistant asthma remains incompletely understood. OBJECTIVE: To determine if failure of asthma to clinically improve with CS is due to a defective response of airway bronchial inflammation to these drugs. METHODS: Twenty-one asthmatics having a decreased baseline FEV1 that improved >or= 30% with inhaled beta2 agonist got bronchial biopsies before and at the end of an oral CS treatment (methylprednisolone 40 mg daily for 14 days). They were arbitrarily divided into two groups according to baseline FEV1 improvement following this treatment: >or= 23% designated as CS-sensitive (CSS) (n = 10) and < 15% as CS-resistant (CSR) (n = 11). RESULTS: Before oral CS, counts of bronchial mucosa inflammatory cells identified by immunohistochemistry (CD3, MBP, tryptase, CD68, neutrophil elastase and CD25 for lymphocytes, eosinophils, mast cells, macrophages, neutrophils and IL-2 receptors, respectively) were similar in CSS and CSR subjects. Oral CS decreased CD3+ cell counts (medians: 60-20 cells/mm(2); P = 0.014) and MBP+ cell counts (medians: 19-4 cells/mm(2); P = 0.03) in CSS asthmatics, but only tryptase+ cell counts in CSR asthmatics (medians: 30-18 cells/mm(2); P = 0.05). Few bronchial neutrophil elastase+ cells were observed and their counts were similar in the two groups of asthmatics before and when on oral CS (all medians: = 2 cells/mm(2)). CONCLUSIONS: These data show that, in these subjects with moderate to severe asthma, lymphocytes and eosinophils constitute most of the inflammatory cells infiltrating the bronchial mucosa. They also demonstrated that clinical impaired response to CS is associated with a persistent bronchial mucosa cellular infiltrate despite oral CS treatment. Additional studies are required to determine the role of this CS-resistant bronchial inflammation in the impaired asthma clinical response to these drugs.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Asthma/immunology , Bronchi/immunology , Glucocorticoids/therapeutic use , Methylprednisolone/therapeutic use , Administration, Inhalation , Administration, Oral , Adrenergic beta-2 Receptor Agonists , Adrenergic beta-Agonists/administration & dosage , Adult , Anti-Inflammatory Agents/administration & dosage , Asthma/diagnosis , Female , Forced Expiratory Volume , Glucocorticoids/administration & dosage , Humans , Inflammation/immunology , Leukocyte Count , Male , Methylprednisolone/administration & dosage , Respiratory Mucosa/immunologyABSTRACT
BACKGROUND: IL-17 is a cytokine that has been reported to be produced by T lymphocytes. In vitro, IL-17 activates fibro-blasts and macrophages for the secretion of GM-CSF, TNF-alpha, IL-1beta, and IL-6. A number of these cytokines are involved in the airway remodeling that is observed within the lungs of asthmatic individuals. OBJECTIVE: In this study, we investigated the expression of IL-17 in sputum and bronchoalveolar lavage specimens obtained from asthmatic subjects and from nonasthmatic control subjects. METHODS: IL-17 was detected through use of immunocytochemistry, in situ hybridization, and Western blot. Bronchial fibroblasts were stimulated with IL-17, and cytokine production and chemokine production were detected through use of ELISA and RT-PCR. RESULTS: Using immunocytochemistry, we demonstrated that the numbers of cells positive for IL-17 are significantly increased in sputum and bronchoalveolar lavage fluids of subjects with asthma in comparison with control subjects (P <.001 and P <.005, respectively). We demonstrated that in addition to T cells, eosinophils in sputum and bronchoalveolar lavage fluids expressed IL-17. Peripheral blood eosinophils were also positive for IL-17, and the level of IL-17 in eosinophils purified from peripheral blood was significantly higher in subjects with asthma than in controls (P <.01). To further investigate the mechanism of action of IL-17 in vivo, we examined the effect of this cytokine on fibroblasts isolated from bronchial biopsies of asthmatic and nonasthmatic subjects. IL-17 did enhance the production of pro-fibrotic cytokines (IL-6 and IL-11) by fibroblasts, and this was inhibited by dexamethasone. Similarly, IL-17 increased the level of other fibroblast-derived inflammatory mediators, such as the alpha-chemokines, IL-8, and growth-related oncogene-alpha. CONCLUSION: Our results, which demonstrate for the first time that eosinophils are a potential source of IL-17 within asthmatic airways, suggest that IL-17 might have the potential to amplify inflammatory responses through the release of proinflammatory mediators such as alpha-chemokines.
Subject(s)
Asthma/immunology , Bronchi/drug effects , Chemokines, CXC , Cytokines/metabolism , Fibroblasts/drug effects , Intercellular Signaling Peptides and Proteins , Interleukin-17/pharmacology , Adult , Bronchi/cytology , Bronchoalveolar Lavage Fluid/immunology , Chemokine CXCL1 , Chemotactic Factors/biosynthesis , Eosinophils/immunology , Female , Fibroblasts/cytology , Growth Substances/biosynthesis , Humans , Interleukin-11/metabolism , Interleukin-17/isolation & purification , Interleukin-6/metabolism , Interleukin-8/biosynthesis , Male , Sputum/immunologyABSTRACT
The effect of eotaxin, a potent eosinophil chemotactic factor, on eosinophil transmigration through a reconstituted basal membrane (Matrigel) was evaluated. Eotaxin induced significant eosinophil transmigration in the presence of 10% fetal bovine serum (FBS) and interleukin-5. Its effect was optimal at 0.01 microM, and it plateaued at 18 h. Eotaxin's effect was greater with eosinophils from asthmatic subjects (61.1 +/- 3.4%) than with eosinophils from normal subjects (38.7 +/- 4.2%) (P < 0.001). Inhibition of metalloproteinases decreased eotaxin-induced transmigration by < or = 10.4%, whereas inhibition of the plasminogen-plasmin system decreased eotaxin's effect by < or = 44.4% (P = 0.0002). Moreover, eotaxin-induced transmigration was largely diminished in medium with low concentrations of serum [0.5% FBS: 6.1 +/- 2.4%; 10% FBS: 40.2 +/- 5.8% (P = 0.0001)] but returned to its initial level with the addition of plasminogen (2 U/mL) to 0.5% FBS (43.1 +/- 6.5%). These data show that eotaxin is an efficient promoter of eosinophil transmigration in vitro, that it is more potent with cells from asthmatics than with normal cells, and that its effect depends predominantly on the activation of the plasminogen-plasmin system.
Subject(s)
Asthma/blood , Cell Movement/drug effects , Chemokines, CC , Chemotactic Factors, Eosinophil/metabolism , Cytokines/metabolism , Eosinophils/drug effects , Fibrinolysin/metabolism , Plasminogen/metabolism , Adult , Arachidonic Acids/metabolism , Arachidonic Acids/pharmacology , Cell Movement/physiology , Chemokine CCL11 , Chemotactic Factors, Eosinophil/pharmacology , Collagen , Cytokines/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Enzyme Activation , Eosinophils/metabolism , Eosinophils/physiology , Female , Humans , Hydroxamic Acids/pharmacology , Kinetics , Laminin , Male , Matrix Metalloproteinase Inhibitors , Platelet Activating Factor/metabolism , Platelet Activating Factor/pharmacology , Proteoglycans , Receptors, CCR3 , Receptors, Cell Surface/biosynthesis , Receptors, Chemokine/biosynthesis , Receptors, Urokinase Plasminogen ActivatorABSTRACT
A previous study suggested that the long-acting beta2-adrenergic agonist salmeterol (SM) had inhibitory effects on bronchial mucosal inflammation 6 hours after allergen exposure. To further evaluate the influence of SM on allergen-induced airway inflammation. We studied, in a randomized, double-blind, cross-over trial, 16 mild asthmatic patients who had a dual asthmatic response to allergen inhalation. Subjects received 50 microg of SM or placebo (P), twice daily for 1 week each, separated by a 2-week wash-out period. At the end of each treatment period, after withholding SM for 24 h, they had a methacholine inhalation test (medication was resumed after the test), followed 24 h later by an AC with the concentration of allergen that had induced a LAR at baseline. Airway inflammation was assessed 24 h after the AC by bronchoalveolar lavage (BAL) (n = 16) and bronchial biopsies (n = 13). As expected, SM improved baseline FEV1 and PC20 (P < or = 0.009) and decreased the allergen-induced early bronchoconstrictive response. There were no significant differences in BAL cell counts after the two treatments. On bronchial biopsies, numbers (median, mm2) of submucosal CD45 (P: 43 +/- 23; SM: 161 +/- 43, P = 0.031), CD45Ro (P: 37 +/- 19; SM: 126 +/- 41, P = 0.047) and AA1 positive cells (P: 38 +/- 6, SM: 65 +/- 17, P = 0.006) were significantly higher after SM than P treatment. The numbers of CD4 (P: 11 +/- 10; SM: 32 +/- 7, P = 0.085), HLA-DR (P: 65 +/- 30; SM: 116 +/- 36, P = 0.079) and EG2 positive cells (P: 25 +/- 15; SM: 38 +/- 26, P = 0.09) tended to increase with SM treatment. In summary, compared to placebo, 1 week of regular use of SM is associated with an increase in bronchial inflammatory cells 24 h after AC. This is in keeping with the recommendation that salmeterol should only be used with an anti-inflammatory agent, particularly in the context of significant allergen exposure.
Subject(s)
Albuterol/analogs & derivatives , Albuterol/administration & dosage , Asthma/drug therapy , Bronchodilator Agents/administration & dosage , Adolescent , Adult , Allergens , Asthma/immunology , Asthma/physiopathology , Cross-Over Studies , Double-Blind Method , Female , Humans , Inflammation , Male , Respiratory System/immunology , Respiratory System/physiopathology , Salmeterol Xinafoate , Treatment OutcomeABSTRACT
The mechanisms of fibrillar collagen accumulation in asthmatic bronchi remain unclear, an imbalance between synthesis and degradation of collagen may be implicated in this process. The aim of this study was to compare the capacities of normal (BNF) and asthmatic (BAF) bronchial fibroblasts to degrade collagen. Metalloproteinases and their inhibitors were measured by ELISA, types I and III procollagen synthesis was determined by liquid RIA and, finally, zymography was used to assess the presence of active and latent forms of MMPs. The capacity of fibroblasts to degrade collagen coated onto latex beads was evaluated by flow cytometry. Our results showed that MMP-2 secretion was significantly higher in BNF when compared to BAF and this was confirmed by gelatin zymography. In BNF culture, TIMP-1 and MMP-1 secretions positively correlated with types I and III procollagen synthesis. However, in BAF, this correlation was negative. This suggests that a balance exists between collagen synthesis and degradation in BNF and that this balance is compromised in BAF. On the other hand, BAF did show significantly reduced capacity to degrade collagen when compared to that of BNF. This reduced phagocytic activity was not associated with a decrease in collagen receptor expression. This study establishes for the first time that a relationship exists between metalloproteinases enzyme dysregulation and the reduced capacity of asthmatic bronchial fibroblast to degrade collagen. These events may shed light on why accumulation of collagen can be observed in asthmatic airways.